Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours

BACKGROUND: Sunitinib is approved worldwide for treatment of advanced pancreatic neuroendocrine tumours (pNET), but no validated markers exist to predict response. This analysis explored biomarkers associated with sunitinib activity and clinical benefit in patients with pNET and carcinoid tumours in...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Br J Cancer
Huvudupphovsmän: Zurita, A J, Khajavi, M, Wu, H-K, Tye, L, Huang, X, Kulke, M H, Lenz, H-J, Meropol, N J, Carley, W, DePrimo, S E, Lin, E, Wang, X, Harmon, C S, Heymach, J V
Materialtyp: Artigo
Språk:Inglês
Publicerad: Nature Publishing Group 2015
Ämnen:
Translational Therapeutics
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4385961/
https://ncbi.nlm.nih.gov/pubmed/25756398
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2015.73
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk